Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin

Acne Clinical Trial

Official title:

RV3278AET0943 Cosmetic Product Efficacy Applied for 8 Weeks in Adults Having Oily and Acne Prone Skin: Comparative Study Versus Not Treated Group

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04873089
• Other study ID #: RV3278A2018243
• Status: Completed
• Start date: September 17, 2018
• Est. completion date: December 21, 2018

Study information

• Verified date: April 2021
• Source: Pierre Fabre Dermo Cosmetique
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate, at different times, the RV3278A - ET0943 cosmetic product efficacy after 8 weeks of application on the face (twice-daily application). At T1 (Baseline), T2 (4 weeks) and T3 (8 weeks), the following assessments are performed: - The reduction of the pilosebaceous follicular ostium size in vivo (pores) on the forehead - The clinical evaluation (count of non inflammatory and inflammatory acne lesions, IGA score) of the face - The reduction in visible follicles - The standardized numerical photographs of face and ¾ right and left profile in normal, parallel polarized, cross polarized and UV light - The analysis of the skin lipids of the forehead - The qualitative and quantitative analysis of the sebum and comedones constituents (nose wings) This is a comparative, open-labelled study, on subjects with oily and acne prone skins on the face. Each group includes 18 subjects.

Description:

This study is monocentric, comparative versus non-treated group, open-labelled, exploratory, conducted in adults having oily and acne prone skin. The study includes 4 visits for each group, including subjects' selection: - V0: Subjects' selection - V1: Baseline inclusion - V2: 4 weeks, follow-up visit - V3: 8 weeks, study end The maximal study duration is 61 days. The front, temporal areas and nose wings are defined as the study interest areas for superficial samples. The evaluation is at 3 times: T1 baseline, T2 at 4 weeks and T3 at 8 weeks of application of RV3278A formula ET0943 with comparison of each time versus baseline. There are twice-daily applications (morning and evening) of the test product on the face.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: December 21, 2018
• Est. primary completion date: December 21, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

1. Criteria related to the population:

• Male or Female aged between 18 and 35 years included
• Subject with phototype I to IV included
• Subject having signed his/her written informed consent for his/her participation in the study
• Subject who is currently not participating in another clinical study
• Subject affiliated to a social security system or health insurance, or is a beneficiary
• For woman of childbearing potential: use of an effective method of contraception and using it during the whole duration of the study

2. Criteria related to diseases and general health:

• Subject with oily, blemished skin and dilated pores on the face including open and closed comedones of the retention type (on the forehead, temporal areas and

nose wings) and some inflammatory lesions:

• Retention aspect: microcomedones and open comedones count on the forehead (> 10)
• Inflammatory aspect: lesions = 10 count on the whole face

Exclusion Criteria:

1. Criteria related to the population:

• For woman of childbearing potential: subject pregnant or breastfeeding or planning to be pregnant during the study
• Subject having already known allergy to latex
• Subject having already known allergy to the test product or associated product components
• Subject having scar(s) or other skin characteristic on the study areas (forehead, temporal areas and nose wings) and which, size is not compatible with the study realization
• Subject who, has planned to apply exfoliating, keratolytic and/or self-tanning products on the face within 2 weeks prior to inclusion.
• Subject who, has planned to be exposed to the natural or artificial UV during the study
• Subject who is not likely to be compliant with study-related requirements
• Subject deprived of freedom by administrative or legal decision or under guardianship

2. Criteria related to diseases and general health:

• Inflammatory or immunological dermatosis (atopic dermatitis, psoriasis, severe inflammatory acne, cutaneous seborrhoeic dermatitis, vitiligo of the face..) of the face, or other dermatological face illness in progress at the time of inclusion on the sample areas (pigmentation of the sample areas by melasma, solar erythema or artificial post UV...)

3. Criteria related to treatments

• Facial treatments :
• Any topical anti-acne antibiotics (topical Erythromycin or topical Dalacin) applied during more than 5 consecutive days within 4 weeks before the inclusion
• Any topical treatment (dermo corticoids, retinoids, antibiotics, antifungals…) ongoing or applied within 4 weeks before the inclusion
• Oral intake of antibiotic, zinc gluconate or hormonal anti-acne treatments, ongoing or taken during more than 5 consecutive days within the month before the inclusion
• Oral intake of isotretinoin within 6 months before the inclusion
• Anti-inflammatory treatments (steroids or no steroids) according to the investigator's assessment
• Hormonal contraception established or modified within 3 months before the inclusion
• Application of skin care product containing exfoliating, keratolytic or self-tanning ingredients applied on the face within 15 days before the inclusion
• Oral treatment (cardiovascular, endocrinal, rheumatological, urogenital, neuropsychiatric, immunosuppressant) established within 2 months before the inclusion not stabilized
• Hygiene, skin care or make-up habits modified within less than one month before the inclusion

Related Conditions & MeSH terms

• Acne
• Acne Vulgaris

Intervention

Other:
• Cosmetic product
It is a comparative study with two parallel groups of subjects: Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face Comparative group: no application of study product or reference product

Locations

Country	Name	City	State
France	Skin Research Centre	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
Pierre Fabre Dermo Cosmetique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the product on lesions count (Lucky method)	Inflammatory and lesions quantification on the whole face	Change from baseline to 8 weeks later, for each group
Secondary	Efficacy of the product on lesions count (Lucky method)	Inflammatory and lesions quantification on the whole face	Change from baseline to 4 weeks later, for each group
Secondary	Forehead acne lesions count (target area)		Change from baseline to 4 weeks and 8 weeks later for each group, on the target area
Secondary	Investigator Global Assessment (IGA) on 5-point scale	Clear = 0, Almost clear = 1, Mild = 2, Moderate = 3, Severe = 4	Change from 4 weeks to 8 weeks later, for each group, on the target area
Secondary	Sebum harvest and analysis	Quantification of free fatty acid (FFA) / triglyceride (TG) ratio by infrared spectroscopy: Forehead sebum was collected on absorbent paper then the lipid composition was analysed by infrared spectroscopy to determine the free fatty acids to triglycerides ratio	At baseline and after one month of tested product treatment
Secondary	Comedones lipid harvest and analysis	Quantification of free fatty acid / triglyceride ratio by GC/MS: Samples were collected with patch on nose wings. Comedones were collected and lipids extracted according to the Bligh & Dyer (Bligh and Dyer, 1959). The biochemical exploration was performed by the screening of neutral lipids on GC/MS	At baseline and after one month of tested product treatment
Secondary	Skin lipids	Measure by FTIR spectroscopy (in vivo non invasive infrared analysis)	Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary	Pilosebaceous follicular ostium size in vivo	Measure by confocal microscope	Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary	Dilated pores on 5-point scale	Absent = 0, Very mild = 1, Mild = 2, Moderate = 3, Severe = 4	Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary	Patient Global Assessment (PGA) on 6-points scale	Clear worsening = 0, slight worsening = 1, no change = 2, slight improvement = 3, clear improvement = 4, total improvement = 5	Change from 4 weeks to 8 weeks later, for each group, on the target area
Secondary	Self product agreement questionnaire	9-question questionnaire with a majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one	At week 8, for tested group
Secondary	Visible follicles quantification by in vivo visualisation methods	Count by multispectral imaging	Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area